Atamyo Therapeutics Reaches Significant Regulatory and Financial Milestones for ATA-100, its Gene Therapy to Treat Limb-Girdle Muscular Dystrophy Type 2I/R9
Additional approval of Clinical Trial Application received from Denmark Danish Medicines Agency (DKMA) Orphan Drug Designation awarded from US FDA and European EMA Non-dilutive public
Source: finanznachrichten.de